Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, open-labeled, controlled, randomized study of recombinant Interleukin-7 (CYT107) treatment to restore and maintain CD4 T-lymphocyte counts above 500 cells/L in HIV-infected patients with CD4 counts remaining between 101-350 cells/mL after at least 2 years of HAART and plasma HIV RNA < 50 copies/mL for 18 months.

Trial Profile

A multicenter, open-labeled, controlled, randomized study of recombinant Interleukin-7 (CYT107) treatment to restore and maintain CD4 T-lymphocyte counts above 500 cells/L in HIV-infected patients with CD4 counts remaining between 101-350 cells/mL after at least 2 years of HAART and plasma HIV RNA < 50 copies/mL for 18 months.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interleukin-7 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms INSPIRE-3
  • Most Recent Events

    • 07 Feb 2016 Pooled analysis of 2 studies including this INSPIRE 3 trial and other INSPIRE 2 study [see CTP 700052537] were published in the Clinical Infectious Diseases.
    • 24 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 17 Oct 2012 Planned End Date changed from 1 Jul 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top